Royal Caribbean Cruises Ltd vs Twist Bioscience Corp — how do they compare? Royal Caribbean Cruises Ltd trades at $286 (market cap $76.75B), while Twist Bioscience Corp trades at $93.82 (market cap $5.97B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 12.9× Twist Bioscience Corp's market cap, and Royal Caribbean Cruises Ltd pays a 1.75% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| RCL | TWST | |
|---|---|---|
Market Cap | $76.75B | $5.97B |
Sector | Consumer Cyclical | Health |
52-Week High | $365.84 | $102.88 |
52-Week Low | $246.71 | $24.16 |
Enterprise Value | $98.03B | $5.89B |
Dividend Yield | 1.75% | — |
Signals from Pluang's Aura AI — not financial advice
Royal Caribbean (RCL) trades at $287.90, near its 52-week high, with a modest 0.33% daily gain. The stock shows strong fundamental momentum, with revenue growing from $8.8B in 2022 to $17.9B in 2025 and net income surging to $4.3B. However, technical indicators signal a bearish trend, with moving averages and oscillators pointing to near-term pressure. Recent news highlights earnings anticipation and board appointments, while analyst consensus remains bullish with a $328 price target.
The outlook for RCL is positive based on robust earnings growth and expanding profit margins, but risks include high debt levels and potential economic sensitivity. Investor sentiment is mixed, with technical weakness offset by strong fundamentals. The stock presents a long-term opportunity if it can maintain operational execution amid competitive and macroeconomic challenges.
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Trailing returns across standard periods
Latest headlines on both assets
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →